KYORIN Pharmaceutical (4569) FY2027 Q1 Earnings Report

Quick View

Executive Summary

Although the decline in revenue was limited, the deterioration in gross margin combined with an increased SG&A expense burden, resulting in a substantial decline in operating income of nearly 60% year on year. Revenue was ¥296.5B (-1.9% YoY), operating income was ¥9.6B (-59.3%), ordinary income was ¥12.4B (-52.7%), and net income was ¥8.2B (-60.8%). The gross margin declined by approximately 2.8pt from the previous year to 41.1%, while the SG&A ratio rose by approximately 1.8pt to 37.8%, which were the primary causes of the decline in operating income. At the ordinary income level, non-operating income, including ¥2.9B in dividend income, provided partial support; however, net income was further compressed by the recognition of ¥1.5B in impairment losses on investment securities as an extraordinary loss.

Factors Affecting Earnings

【Revenue】Revenue was ¥296.5B, representing a 1.9% decline from the same period of the previous year. The Company reports a single segment and does not disclose segment-level factors affecting changes; however, while cost of sales increased by 3.0% year on year to ¥174.8B, revenue declined, suggesting that deterioration in the price mix and cost overruns may have pressured gross profit. Gross profit was ¥121.8B (¥132.6B in the previous year), resulting in a gross margin of 41.1%, approximately 2.8pt below the previous year's 43.9%.

【Profit and Loss】SG&A expenses were ¥112.1B (¥108.9B in the previous year, +2.9%), increasing despite the decline in revenue. Consequently, the SG&A ratio rose to 37.8% from 36.0% in the previous year, an increase of approximately 1.8pt. As a result, operating income was ¥9.6B (-59.3%), and the operating margin deteriorated substantially to 3.3% from 7.8% in the previous year. Ordinary income was ¥12.4B (-52.7%), with ¥3.4B in non-operating income, primarily comprising ¥2.9B in dividend income, offsetting part of the decline in operating income. At the net income level, extraordinary losses of ¥1.5B, including ¥1.5B in impairment losses on investment securities, reduced profit before tax. After an effective tax burden of approximately 30.6%, net income was ¥8.2B (-60.8%). The gap between ordinary income and net income reached approximately 33.6%, indicating a significant impact from extraordinary gains and losses. Overall, the results represented declines in both revenue and profit, confirming a structural deterioration in profitability.

Segment Analysis

The Company reports a single segment, and segment-level revenue and profit information has been omitted.

Key Financial Indicators

【Profitability】The operating margin was 3.3%, down approximately 4.6pt from 7.8% in the same period of the previous year, while the net profit margin also deteriorated significantly to 2.8% from 6.9% in the previous year. The decline in gross margin to 41.1% (43.9% in the previous year) coincided with an increase in the SG&A ratio to 37.8% (36.0% in the previous year), with both the cost structure and earnings power acting as downward pressures.【Cash Flow Quality】Comprehensive income was ¥0.3B, substantially below net income of ¥8.2B, primarily because the valuation difference on securities deteriorated to -¥8.2B. Given that the gap between ordinary income and net income was approximately 33.6%, the quality of current-period earnings was strongly affected by extraordinary gains and losses and valuation-related items.【Investment Efficiency】ROE was 0.6%, and capital efficiency remained low, reflecting the small absolute level of net income. Total assets were ¥1886.1B and net assets were ¥1403.0B, both slightly lower than the previous year, indicating a decline in profit without an expansion in the asset base.【Financial Soundness】The equity ratio rose to 74.4% from 72.9% in the previous year, and the financial base remained conservative. Cash and deposits increased to ¥136.7B from ¥118.0B in the previous year, while long-term borrowings were largely flat at ¥203.9B, indicating that financial leverage remained low and stable.

Cash Flow Analysis

As no cash flow statement is disclosed, cash trends are assessed based on changes in the balance sheet during the period. Cash and deposits increased by ¥18.7B to ¥136.7B from ¥118.0B in the same period of the previous year, while accounts receivable and notes receivable declined by ¥69.0B to ¥404.4B from ¥473.4B in the previous year. Accounts payable and notes payable also declined by ¥27.6B to ¥116.8B from ¥144.4B in the previous year. The reduction in accounts receivable may have contributed to the increase in cash balances, although accounts payable also declined simultaneously, indicating cash outflows on the procurement and payment side. Inventories were ¥233.8B, broadly flat compared with ¥238.7B in the previous year, with no significant change in inventory levels. Property, plant and equipment was ¥301.9B and investment securities were ¥174.4B, both lower than in the previous year, suggesting that the recognition of impairment losses and asset reductions contributed to the contraction on the asset side. Long-term borrowings were ¥203.9B, largely in line with the previous year, and no major changes in financing or repayments through financing activities were identified.

Earnings Quality

Current-period profit was primarily affected by a slowdown in core operating performance, and earnings quality has somewhat deteriorated after taking into account the impact of non-operating income and extraordinary gains and losses. Dividend income accounted for ¥2.9B of the ¥3.4B in non-operating income, and remained limited at approximately 1.1% of revenue; therefore, the contribution of external factors to ordinary income was not substantial. Meanwhile, ¥1.5B in extraordinary losses consisted largely of impairment losses on investment securities, which are valuation-related losses not accompanied by cash outflows. As a result, net income was ¥8.2B compared with ordinary income of ¥12.4B, representing a gap of approximately 33.6%. Comprehensive income was ¥0.3B, substantially below net income, primarily because the valuation difference on securities deteriorated. Accordingly, a considerable divergence arose between current-period earnings and other comprehensive income components.

Earnings Forecast and Guidance

Progress against the full-year plan was 24.3% for revenue (¥296.5B/¥1218.0B), which was broadly at a standard level, while progress was 48.2% for operating income (¥9.6B/¥20.0B) and 54.0% for ordinary income (¥12.4B/¥23.0B). Profit indicators therefore showed significantly more front-loaded progress than revenue. This difference may reflect a conservative plan incorporating increases in SG&A expenses and costs in the second half, or the seasonality of expense recognition. No revisions were made to the earnings forecast or dividend forecast during the quarter, and the Company maintained its initial plan. Going forward, trends in the gross margin and SG&A ratio from Q2 onward will be key to assessing the achievability of the full-year plan.

Shareholder Returns

The Company's annual dividend forecast is ¥10.00 per share, down from the previous fiscal year's actual dividend of ¥20. Based on the Company's forecast EPS of ¥26.11, the payout ratio is approximately 38.3% (¥10.00/¥26.11), representing a level sufficiently covered by the profit level for the fiscal year. With cash and deposits of ¥136.7B and an equity ratio of 74.4%, the Company has a strong financial base and sufficient capacity to fund dividends. No revision was made to the dividend forecast during the quarter.

Risk Factors

1. Profitability deterioration risk: The gross margin declined by approximately 2.8pt from the previous year to 41.1%, while the SG&A ratio rose by approximately 1.8pt to 37.8%. As higher costs amid declining revenue reduced the operating margin to 3.3%, further deterioration in earnings power is a concern if improvements in the price mix and cost structure do not progress.

2. Working capital efficiency risk: Accounts receivable of ¥404.4B and inventories of ¥233.8B each represent substantial amounts relative to revenue of ¥296.5B. If inventory and accounts receivable turnover periods lengthen, cash generation may come under pressure.

3. Valuation fluctuation risk for securities: The Company holds ¥174.4B in investment securities and recognized ¥1.5B in impairment losses as an extraordinary loss during the period. The valuation difference on securities was -¥8.2B, weighing on comprehensive income, indicating that market fluctuations have a relatively significant impact on the financial statements.

Industry Benchmark (For Reference; Compiled by the Company)

Profitability and Returns

Both the operating margin and net profit margin were substantially below the industry median, placing the Company's profitability at the lower end of the industry.

Growth and Capital Efficiency

The revenue growth rate was substantially below the industry median, indicating that the stagnation of top-line growth was particularly pronounced compared with peers.

※Source: Compiled by the Company

Key Takeaways from the Financial Results

1. The operating margin of 3.3% was 14.3pt below the industry median of 17.5%. The results indicate weakness in the margin structure, driven by the combination of a lower gross margin and a higher SG&A ratio.

2. Progress against the full-year plan was significantly more front-loaded on the profit side, at 48.2% for operating income and 54.0% for ordinary income versus 24.3% for revenue, suggesting a conservative plan that assumes higher expenses in the second half.

3. Although the financial base is strong, with an equity ratio of 74.4% and cash and deposits of ¥136.7B, ROE of 0.6% and comprehensive income of ¥0.3B indicate low levels of capital efficiency and earnings quality. The recovery trend in profitability will therefore remain a key focus.

Theoretical Share Price (Reference Value)

This is a reference range mechanically calculated solely from publicly disclosed data using a residual income model (Ohlson-type model with an explicit 5-year fade). It is not a forecast of the market share price or a recommendation of any specific investment action.

Sensitivity: ¥1,840–¥1,946 at cost of equity ±1%, and ¥1,874–¥1,903 at ω±0.1.

Notes:

• Because progress toward forecast full-year net income (55%) exceeds the standard level (25%), forecast EPS has been adjusted upward within a maximum range of +10% (because companies with front-loaded progress tend to exceed forecasts; adjustments may be excessive for businesses with strong seasonality).
• Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets at the end of the quarter are used (there is a timing difference relative to the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model / Interest Rate Reference Month: 2026-06 / This value does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, and you should consult a professional as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2027 Q1 earnings were weak, with modest revenue erosion translating into a sharp contraction in operating and net profit. Revenue declined 1.9% YoY to ¥29.65bn. Operating income fell 59.3% YoY to ¥0.96bn. Net income attributable to owners declined 60.8% YoY to ¥0.82bn. Gross profit decreased 8.2% YoY to ¥12.18bn despite only a 1.9% revenue decline. Gross margin contracted by 275bp YoY to 41.1%. SG&A expense fell 3.4% YoY to ¥11.21bn, but the reduction was insufficient to offset the gross-profit decline. Consequently, operating margin compressed by 458bp YoY to 3.2%. Net margin compressed by 417bp YoY to 2.8%. Dividend income of ¥0.29bn represented the main component of non-operating income and supported ordinary income of ¥1.24bn. Ordinary income nevertheless fell 52.7% YoY, confirming that the profit weakness was primarily operational rather than financing-driven. Extraordinary income of ¥0.10bn was more than offset by extraordinary losses of ¥0.15bn, creating a ¥0.05bn net non-recurring loss. Comprehensive income was only ¥0.03bn, substantially below net income because of negative valuation differences on securities. The balance sheet remains highly liquid, with a 518.2% current ratio and 0.34x debt-to-equity ratio. Full-year guidance calls for revenue of ¥121.80bn, operating income of ¥2.00bn and net income of ¥1.50bn, implying that Q1 already achieved 48.2% of the operating-profit target and 54.9% of the net-income target. The unusually high first-quarter earnings progress versus guidance indicates a forecast that embeds materially lower profitability over the remainder of the fiscal year, or conservatism in the unchanged forecast. The central issue for subsequent quarters is whether gross-margin pressure and weak operating leverage can be reversed while maintaining pharmaceutical product demand and inventory discipline.

Profitability Analysis

The reported annualized DuPont ROE is 2.4%, decomposed into a 2.8% net profit margin, 0.629x asset turnover and 1.34x financial leverage. The principal constraint is profitability rather than leverage: a 2.8% net margin is below the 3% concern threshold, while leverage remains conservative. Annualized asset turnover of 0.629x is moderate, but it does not compensate for the low earnings margin on a ¥188.61bn asset base. Financial leverage of 1.34x is modest and indicates that the company is not relying on aggressive balance-sheet gearing to support returns. EBIT margin was 3.2%, triggering the low-operating-efficiency alert because it is below the 5% concern benchmark. The root cause is gross-margin compression, as cost of sales rose 4.0% YoY while revenue declined 1.9% YoY. Gross margin fell from 43.9% to 41.1%, and operating margin fell from 7.8% to 3.2%. SG&A declined 3.4% YoY, faster than revenue, but it consumed 37.8% of revenue versus 36.0% a year earlier because the gross-profit decline was larger than the SG&A reduction. This indicates negative operating leverage at the gross-profit level. The ROIC alert of 1.8% likewise signals poor capital productivity relative to the 5% warning threshold, with operating earnings insufficient relative to the capital employed. The low ROIC is especially important for a pharmaceutical company because product, manufacturing and investment assets require returns adequate to fund future development and lifecycle investment. Interest coverage of 16.34x remains strong, so debt servicing is not the source of the weak return profile. The five-factor DuPont interest burden of 1.231 reflects non-operating income exceeding interest expense rather than financial stress, with ¥0.29bn of dividend income materially supporting pre-tax earnings. The effective tax rate was 30.6%, and the tax burden of 0.694 was broadly normal. Profitability recovery depends chiefly on restoring gross margin and converting the lower SG&A base into operating leverage.

Growth Assessment

Top-line momentum was soft, with Q1 revenue down 1.9% YoY to ¥29.65bn. The much larger 59.3% decline in operating income demonstrates that the earnings shortfall was not proportional to revenue but reflected adverse cost and margin dynamics. Cost of sales increased by ¥0.50bn YoY, whereas revenue declined by ¥0.57bn, reducing gross profit by ¥1.08bn. Full-year revenue guidance of ¥121.80bn implies a 24.3% Q1 progress rate, broadly consistent with a normal 25% seasonal benchmark. Q1 operating-income progress was 48.2% against the full-year ¥2.00bn target, 23.2 percentage points above the standard 25% progress rate. Q1 net-income progress was 54.9% against the ¥1.50bn target, 29.9 percentage points above the standard benchmark. The guidance therefore assumes a sharply lower earnings run-rate after Q1 despite broadly normal sales progress. Management has not revised either earnings or dividend guidance. Dividend income increased to ¥0.29bn from ¥0.23bn and partly cushioned ordinary income, but it does not replace recurring operating-profit growth. For a pharmaceutical business, sustaining growth will depend on product demand, pricing resilience, lifecycle management and the ability to absorb manufacturing and selling costs. The current quarter provides no evidence that revenue growth alone is sufficient to restore margins; gross-profit recovery is the more immediate requirement.

Financial Health

Financial health is strong from a liquidity and solvency perspective. Current assets of ¥130.09bn exceeded current liabilities of ¥25.11bn by ¥104.99bn, producing a 518.2% current ratio. The 425.0% quick ratio confirms that liquidity remains robust even excluding inventories. Cash and deposits of ¥13.67bn covered short-term loans of ¥2.60bn by 5.26x. Short-term debt represented only 11.3% of interest-bearing debt, limiting near-term refinancing concentration. Interest-bearing debt totaled ¥22.99bn, including ¥20.39bn of long-term loans, while debt-to-equity was a conservative 0.34x. Debt/capital was 14.1%, well below the 40% investment-grade reference threshold. Interest coverage was 16.34x, demonstrating ample capacity to service reported interest expense from EBIT. Current liabilities declined by ¥4.26bn YoY, principally alongside lower trade payables and tax liabilities, while long-term loans remained essentially unchanged. Total equity was ¥140.30bn and represented 74.4% of total assets, providing a substantial loss-absorption buffer. The principal balance-sheet consideration is not liquidity but low operating returns on the capital base. Investment securities of ¥17.45bn and accumulated other comprehensive income of ¥10.56bn expose book value and comprehensive income to market-value movements. Negative securities valuation effects contributed to comprehensive income of only ¥0.03bn despite ¥0.82bn of net income.

Notable B/S Changes

Total assets: -¥6.85bn (-3.5%) YoY to ¥188.61bn, mainly reflecting lower current assets and investment securities. Trade receivables: -¥6.90bn (-14.6%) YoY to ¥40.44bn; the reduction is constructive, although the reported 124-day DSO remains elevated. Current assets: -¥5.05bn (-3.7%) YoY to ¥130.09bn, while the current ratio remained exceptionally strong at 518.2%. Investment securities: -¥1.42bn (-7.5%) YoY to ¥17.45bn; negative securities valuation effects contributed to weak comprehensive income. Work in process: +¥1.27bn (+8.6%) YoY to ¥16.03bn despite lower revenue, increasing the need to monitor inventory conversion and demand alignment. Provision for bonuses: -¥1.04bn (-48.2%) YoY to ¥1.12bn, reducing current obligations. Income taxes payable: -¥0.48bn (-53.5%) YoY to ¥0.42bn, consistent with lower profitability and tax expense. Total equity: -¥2.12bn (-1.5%) YoY to ¥140.30bn, with negative OCI partly offsetting retained earnings.

Cash Flow Quality

Working-capital efficiency is a material earnings-quality and cash-conversion concern. The high receivable-days alert of 124 days is well above the 60-day reference level, indicating that a significant portion of quarterly revenue remains tied up in trade receivables. Trade receivables were ¥40.44bn, equal to 21.4% of total assets. Although receivables declined ¥6.90bn YoY, their absolute balance remains high relative to quarterly revenue. The inventory-days alert of 351 days is substantially above the 90-day reference threshold and indicates potentially slow conversion of inventory into sales under the reported methodology. A second inventory-days alert of 122 days also exceeds its 60-day benchmark; under either reported methodology, inventory intensity is elevated. Finished goods were ¥23.38bn and work in process was ¥16.03bn, while raw materials were ¥27.80bn. Work in process increased ¥1.27bn YoY, or 8.6%, despite weaker revenue, warranting monitoring for production-demand alignment. The cash conversion cycle alert of 414 days is well above the 120-day reference benchmark. Its root cause is the combination of long receivable collection and inventory holding periods, only partly offset by supplier financing through ¥11.68bn of trade payables. This can increase cash needs and raises the risk that accounting earnings do not translate promptly into operating cash generation. In pharmaceuticals, elevated inventory may also create exposure to demand forecasting error, product obsolescence and inventory write-downs. Lower receivables and finished-goods inventory year on year are constructive directional movements, but the reported day metrics remain well above normal efficiency thresholds.

Dividend Sustainability

The unchanged full-year dividend forecast is ¥25.00 per share. Against forecast EPS of ¥26.11, the implied dividend payout ratio is approximately 95.7%. This is below 100% but materially above the 60% sustainability reference level, leaving limited earnings retention under the current profit outlook. The high prospective payout places greater importance on achieving the full-year net-income target of ¥1.50bn. Q1 EPS was ¥14.35, equivalent to 54.9% of forecast full-year EPS, but quarterly earnings annualization is not appropriate for dividend coverage because management guidance already assumes a materially lower profit run-rate after Q1. Retained earnings were substantial at ¥130.22bn, and the company has a strong liquidity position, which provides balance-sheet capacity to maintain distributions. However, the reduced operating margin and low 1.8% ROIC weaken the quality of internally generated returns supporting shareholder distributions. Dividend sustainability will therefore depend on stabilization of recurring operating earnings and working-capital conversion rather than solely on the current cash and equity buffer.

Risk Assessment

Business risks include Margin risk: cost of sales rose 4.0% YoY while revenue declined 1.9% YoY, compressing gross margin by 275bp and operating margin by 458bp., Pharmaceutical pricing, reimbursement reform, generic competition and product-lifecycle risk could further pressure revenue and gross margin., Working-capital execution risk is elevated: reported DSO of 124 days, inventory days of 351 days and cash conversion cycle of 414 days indicate slow cash conversion., Inventory-demand mismatch risk is heightened by ¥16.03bn of work in process, which increased 8.6% YoY despite lower Q1 revenue., Investment-income sensitivity: dividend income of ¥0.29bn accounted for most non-operating income and supported ordinary earnings outside core operations..

Financial risks include Capital-efficiency risk is high, with reported ROIC of 1.8% and annualized ROE of 2.4%, both below return benchmarks., Comprehensive-income volatility is evident: net income of ¥0.82bn was largely offset by negative OCI, leaving comprehensive income at only ¥0.03bn., Investment securities of ¥17.45bn and accumulated other comprehensive income of ¥10.56bn create exposure to securities-market valuation movements., Prospective dividend coverage is tight on earnings, with the ¥25.00 forecast DPS implying a 95.7% payout ratio based on forecast EPS..

Key concerns include Highest priority: recovery in gross margin and operating margin, as this was the dominant driver of the 59.3% operating-income decline., High priority: whether the elevated receivable, inventory and cash-conversion-cycle metrics translate into weaker cash realization or inventory valuation pressure., Moderate priority: the unchanged full-year forecast requires a sharp decline in profit contribution after Q1, since operating-income progress is already 48.2% at the first-quarter stage., Moderate priority: low operating efficiency and ROIC reduce the capacity to self-fund pharmaceutical development, product investment and shareholder returns over time..

Investment Implications

Key takeaways include Q1 revenue weakness was limited, but gross-margin deterioration caused a disproportionate earnings decline., The operating margin of 3.2% and ROIC of 1.8% are below stated efficiency benchmarks., Liquidity, leverage and interest-servicing capacity remain strong, mitigating near-term financial-stress risk., High receivable days, inventory days and cash conversion cycle are key indicators of operational cash-conversion risk., The implied 95.7% forecast dividend payout ratio leaves limited earnings headroom if operating-profit recovery falls short..

Metrics to watch include Gross margin and cost-of-sales growth relative to revenue growth, Operating margin recovery from 3.2%, Trade receivables and DSO from the reported 124 days, Finished goods, work in process and inventory-day metrics, Cash conversion cycle from the reported 414 days, Progress against full-year operating-income guidance of ¥2.00bn, Dividend coverage versus forecast EPS of ¥26.11.

Regarding relative positioning, The company presents a conservative balance-sheet profile, with exceptionally high liquidity, low leverage and strong interest coverage, but its current profitability and capital efficiency are weak for a pharmaceutical manufacturer. Relative positioning is therefore characterized by financial resilience offset by sub-scale operating returns, significant working-capital intensity and a high earnings-based dividend commitment.